A Comparison of the Efficacy and Safety of Irbesartan/Hydrochlorothiazide Combination Therapy with Irbesartan Monotherapy in the Treatment of Moderate or Severe Hypertension in Diabetic and Obese Hypertensive Patients: A Post-Hoc Analysis Review

References

• . Adler AI, Stratton IM, Neil HA,. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ. 2000;321(7258):412–419
   PubMed Web of Science ®Google Scholar
• . Bays HE, Chapman RH, Grandy S; SHIELD Investigators' Group. The relationship of body mass index to diabetes mellitus, hypertension and dyslipidaemia: comparison of data from two national surveys. Int J Clin Pract. 2007;61(5):737–747
   PubMed Web of Science ®Google Scholar
• . Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360(9349):1903–1913
   PubMed Web of Science ®Google Scholar
• . Livingston EH, Ko CY. Effect of diabetes and hypertension on obesity-related mortality. Surgery. 2005;137(1):16–25
   PubMed Web of Science ®Google Scholar
• . Manson JE, Willett WC, Stampfer MJ,. Body weight and mortality among women. N Engl J Med. 1995;333(11):677–685
   PubMed Web of Science ®Google Scholar
• . Dahlof B, Devereux RB, Kjeldsen SE,; LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359(9311):995–1003
   PubMed Web of Science ®Google Scholar
• . Kjeldsen SE, Julius S, Brunner H,. Characteristics of 15,314 hypertensive patients at high coronary risk. The VALUE trial. The Valsartan Antihypertensive Long-term Use Evaluation. Blood Press. 2001;10(2):83–91
   PubMed Web of Science ®Google Scholar
• . Lonati C, Morganti A, Comarella L, Mancia G, Zanchetti A; IPER-DIA Study Group. Prevalence of type 2 diabetes among patients with hypertension under the care of 30 Italian clinics of hypertension: results of the (Iper)tensione and (dia)bete study. J Hypertens. 2008;26(9):1801–1808
   PubMed Web of Science ®Google Scholar
• . Neutel JM, Saunders E, Bakris GL,; INCLUSIVE Investigators. The efficacy and safety of low- and high-dose fixed combinations of irbesartan/hydrochlorothiazide in patients with uncontrolled systolic blood pressure on monotherapy: the INCLUSIVE trial. J Clin Hypertens (Greenwich). 2005;7(10):578–586
   PubMedGoogle Scholar
• . Bramlage P, Pittrow D, Wittchen HU,. Hypertension in overweight and obese primary care patients is highly prevalent and poorly controlled. Am J Hypertens. 2004;17(10):904–910
   PubMed Web of Science ®Google Scholar
• . Mancia G, Korlipara K, van Rossum P, Villa G, Silvert B. An ambulatory blood pressure monitoring study of the comparative antihypertensive efficacy of two angiotensin II receptor antagonists, irbesartan and valsartan. Blood Press Monit. 2002;7(2):135–142
   PubMed Web of Science ®Google Scholar
• . Davy KP, Hall JE. Obesity and hypertension: two epidemics or one? Am J Physiol Regul Integr Comp Physiol. 2004;286(5):R803–R813
   Web of Science ®Google Scholar
• . Thomson SC, Vallon V, Blantz RC. Kidney function in early diabetes: the tubular hypothesis of glomerular filtration. Am J Physiol Renal Physiol. 2004;286(1):F8–F15
   Web of Science ®Google Scholar
• . Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ. 1998;317(7160):703–713
   PubMed Web of Science ®Google Scholar
• . Hansson L, Zanchetti A, Carruthers SG,. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998;351(9118):1755–1762
   PubMed Web of Science ®Google Scholar
• . Chobanian AV, Bakris GL, Black HR,; National Heart, Lung, and Blood Institute Joint National Committee of Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289(19):2560–2572
   PubMed Web of Science ®Google Scholar
• . Mancia G, De Backer G, Dominiczak A,; Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25(6):1105–1187
   PubMed Web of Science ®Google Scholar
• . Neutel JM, Franklin SS, Oparil S, Bhaumik A, Ptaszynska A, Lapuerta P. Efficacy and safety of irbesartan/HCTZ combination therapy as initial treatment for rapid control of severe hypertension. J Clin Hypertens (Greenwich). 2006;8(12):850–857
   PubMedGoogle Scholar
• . Neutel JM, Franklin SS, Lapuerta P, Bhaumik A, Ptaszynska A. A comparison of the efficacy and safety of irbesartan/HCTZ combination therapy with irbesartan and HCTZ monotherapy in the treatment of moderate hypertension. J Hum Hypertens. 2008;22(1):266–274
   PubMed Web of Science ®Google Scholar
• . Sharma AM, Bramlage P, Kirch W. Antihypertensive effect of irbesartan and predictors of response in obesity-associated hypertension: a prospective, open-label study. Clin Drug Investig. 2005;25(12):765–776
   PubMed Web of Science ®Google Scholar
• . Bramlage P, Pittrow D, Kirch W. The effect of irbesartan in reducing cardiovascular risk in hypertensive type 2 diabetic patients: an observational study in 16,600 patients in primary care. Curr Med Res Opin. 2004;20(10):1625–1631
   PubMed Web of Science ®Google Scholar
• . Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. JAMA. 1967;202(11):1028–1034
   PubMed Web of Science ®Google Scholar
• . Pool JL, Glazer R, Weinberger M, Alvarado R, Huang J, Graff A. Comparison of valsartan/hydrochlorothiazide combination therapy at doses up to 320/25 mg versus monotherapy: a double-blind, placebo-controlled study followed by long-term combination therapy in hypertensive adults. Clin Ther. 2007;29(1):61–73
   PubMed Web of Science ®Google Scholar
• . Sun NL, Jing S, Chen J. The control rate of irbesartan/hydrochlorothiazide combination regimen in the treatment of Chinese patients with mild to moderate hypertension[in Chinese]. Zhonghua Xin Xue Guan Bing Za Zhi. 2005;33(7):618–621
   PubMedGoogle Scholar
• . Mancia G, Grassi G. Systolic and diastolic blood pressure control in antihypertensive drug trials. J Hypertens. 2002;20(8):1461–1464
   PubMed Web of Science ®Google Scholar
• . Bakris GL, Mensah GA. Pathogenesis and clinical physiology of hypertension. Cardiol Clin. 2002;20(2):195–206
   PubMedGoogle Scholar
• . Weinberger MH, White WB, Ruilope LM,. Effects of eplerenone versus losartan in patients with low-renin hypertension. Am Heart J. 2005;150(3):426–433
   PubMed Web of Science ®Google Scholar
• . Weir MR. Population characteristics and the modulation of the renin-angiotensin system in the treatment of hypertension. J Hum Hypertens. 1997;11(1):17–21
   PubMed Web of Science ®Google Scholar
• . Standards of medical care in diabetes—2011. Diabetes Care. 2011;34( suppl 1):S11–S61
   PubMed Web of Science ®Google Scholar
• . Berl T, Hunsicker LG, Lewis JB,; Irbesartan Diabetic Nephropathy Trial Collaborative Study Group. Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Ann Intern Med. 2003;138(7):542–549
   PubMed Web of Science ®Google Scholar
• . Lewis EJ, Hunsicker LG, Clarke WR,; Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345(12):851–860
   PubMed Web of Science ®Google Scholar
• . Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P; Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345(12):870–878
   PubMed Web of Science ®Google Scholar
• . Pohl MA, Blumenthal S, Cordonnier DJ,. Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations. J Am Soc Nephrol. 2005;16(10):3027–3037
   PubMed Web of Science ®Google Scholar
• . Narkiewicz K. Diagnosis and management of hypertension in obesity. Obes Rev. 2006;7(2):155–162
   PubMed Web of Science ®Google Scholar
• . Berlowitz DR, Ash AS, Hickey EC,. Inadequate management of blood pressure in a hypertensive population. N Engl J Med. 1998;339(27):1957–1963
   PubMed Web of Science ®Google Scholar
• . Weber MA, Julius S, Kjeldsen SE,. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet. 2004;363(9426):2049–2051
   PubMed Web of Science ®Google Scholar